Sotorasib made a durable clinical benefit which an objective response and disease control occurred in 37.1% and 80.5% of patients with previously treated KRAS-mutant NSCLC, and median PFS (mPFS) and mOS was 6.8 and 12.5 months, respectively [37]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.